BioCryst Pharmaceuticals | BCRX - 普通股股本

金融业

USD

USD 465.05M

现金及等价物

USD 171.59M

USD 9.52M

USD 373.63M

USD 195.39M

USD 828.6M

股息收益率

0

USD 260.39M

USD 51.7M

536

EPS每股收益

USD 1.17

股本和储备

USD -553.84M

USD 153.05M

债务利息支出

USD 14.14M

USD -0.13

USD 395.2M

USD 1.74B

USD 245.85M

USD -553.84M

USD 260.39M

普通股股本

USD 213.06M

6.06

USD 248.02M

USD 406.56M

销售和管理费用

USD 95.78M

USD 5.99M

贸易债权人

USD 10.96M

应收帐款人

USD 106.82M

	普通股股本	更改		日
Alnylam Pharmaceuticals	USD 133.44M		1.07M	2026-03
BioCryst Pharmaceuticals	USD 213.06M		2.54M	2025-12
Chugai Pharma	JPY 1.65B		50K	2026-03
Daiichi Sankyo	JPY 1.85B		9K	2025-12
DBV Technologies	USD 136.82M		51.98K	2025-09
Enanta Pharmaceuticals	USD 212K		1000	2023-12
Gilead Sciences	USD 1.24B		1000K	2026-03
GlaxoSmithKline	GBP 4.05B		20.6M	2026-03
Glaxosmithkline	GBP 4.08B		49.43M	2025-12
Incyte	USD 199.95M		1.49M	2026-03
Ionis Pharmaceuticals	USD 165.9M		3.93M	2026-03
Karyopharm Therapeutics	USD 18.31M		18.3M	2025-12
Neurocrine Biosciences	USD 100.6M		500K	2026-03
Novavax	USD 162.58M		106K	2025-12
PTC Therapeutics	USD 81.47M		1.54M	2025-12
Regeneron Pharmaceuticals	USD 105M		300K	2026-03
Roche Holding	CHF 795.62M		699.54K	2025-12
Sarepta Therapeutics	USD 105.57M		607K	2026-03
Ultragenyx Pharmaceutical	USD 98.3M		1.7M	2026-03
Vertex Pharmaceuticals	USD 254.2M		200K	2026-03